#Thinksabio latest news
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184
Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025Oral presentation will include the full 96-week and post-treatment follow up data from the Phase 1 monotherapy study of ALG-000184